Novo-Nordisk A/S
NVO Real Time Price USD$NVO is featured in our Tom Carper strategy.
All StrategiesRecent trades of NVO by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in NVO holdings by institutional investors
Quarterly net insider trading by NVO's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$1,730,000 Oct 20, 2025 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark Taxation/Internal Revenue Code Tariff (miscellaneous tariff bills)
-
$1,050,000 Jul 16, 2025 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark Taxation/Internal Revenue Code Tariff (miscellaneous tariff bills)
-
$2,330,000 Apr 18, 2025 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark
-
$1,240,000 Jan 17, 2025 Issue: Health Issues Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark
-
$780,000 Oct 18, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations Health Issues
-
$1,060,000 Jul 19, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations Health Issues
-
$1,490,000 Apr 18, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations Health Issues
-
$2,180,000 Apr 18, 2024 Issue: Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations Health Issues
-
$60,000 Feb 07, 2024 Issue: Budget/Appropriations Pharmacy Medicare/Medicaid Health Issues
-
$600,000 Oct 19, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid Budget/Appropriations Health Issues
NVO Estimated quarterly lobbying spending
NVO Revenue by Segment or Geography
New NVO patent grants
-
Patent Title: Injection device Sep. 09, 2025
-
Patent Title: Injection device Feb. 18, 2025
-
Patent Title: Pill bottle Oct. 29, 2024
-
Patent Title: Pill Aug. 20, 2024
-
Patent Title: Logging device for drug delivery device Feb. 28, 2023
-
Patent Title: Injection device Jun. 21, 2022
-
Patent Title: Injector pen May. 24, 2022
-
Patent Title: Tablet formulation comprising semaglutide and a delivery agent Jun. 12, 2018
-
Patent Title: Stable glp-1 based glp-1/glucagon receptor co-agonists Jun. 05, 2018
-
Patent Title: Enterokinase cleavable polypeptides May. 29, 2018
-
Patent Title: Factor viii polypeptide titers in cell cultures May. 29, 2018
-
Patent Title: Liraglutide in cardiovascular conditions May. 15, 2018
-
Patent Title: Stable glucagon analogues and use for treatment of hypoglycaemia May. 08, 2018
-
Patent Title: Frontloaded drug delivery device with dynamic axial stop feature May. 01, 2018
-
Patent Title: Mic-1 fusion proteins and uses thereof May. 01, 2018
-
Patent Title: Medical injection device comprising a secondary safety limiter Apr. 24, 2018
-
Patent Title: Medical device and cartridge Apr. 24, 2018
-
Patent Title: Human cd30 ligand antigen binding proteins Mar. 27, 2018
-
Patent Title: Glp-1 compounds Mar. 20, 2018
-
Patent Title: Arrangement for sequential delivery of fluid volumes Mar. 20, 2018
-
Patent Title: Antibodies that bind urokinase plasminogen activator Mar. 06, 2018
-
Patent Title: Injection device with a sliding scale Feb. 27, 2018
-
Patent Title: Medical injection device Feb. 27, 2018
-
Patent Title: Spring driven injection device Feb. 27, 2018
-
Patent Title: Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor Feb. 20, 2018
-
Patent Title: Derivative of an insulin analogue Feb. 20, 2018
-
Patent Title: Fgf21 derivatives and uses thereof Feb. 20, 2018
-
Patent Title: Drug filled delivery assembly Feb. 13, 2018
-
Patent Title: Method of treating diabetes mellitus Feb. 06, 2018
-
Patent Title: Anti-kir antibodies, formulations, and uses thereof Jan. 30, 2018
-
Patent Title: Injection device with an end of dose feedback mechanism Jan. 09, 2018
-
Patent Title: Spring driven injection device Jan. 09, 2018
-
Patent Title: Injection device Jan. 02, 2018
-
Patent Title: Medical injection device Dec. 05, 2017
-
Patent Title: Rotary sensor module with axial switch Dec. 05, 2017
-
Patent Title: Spring-loaded injection device with an injection button Dec. 05, 2017
-
Patent Title: Dial-down mechanism for wind-up pen Apr. 11, 2017
-
Patent Title: Insulin derivatives Oct. 04, 2016
-
Patent Title: Injection device Sep. 06, 2016
-
Patent Title: Injector display with graphical user interface Jul. 26, 2016
-
Patent Title: Injection device Jun. 07, 2016
-
Patent Title: Container for medical purposes Dec. 29, 2015
-
Patent Title: Aryl carbonyl derivatives as therapeutic agents Sep. 15, 2015
-
Patent Title: Injection device Jul. 14, 2015
-
Patent Title: Injection device May. 19, 2015
-
Patent Title: Injection device Mar. 17, 2015
-
Patent Title: Heteroaryl-ureas and their use as glucokinase activators Oct. 07, 2014
-
Patent Title: Needle hub Jan. 29, 2013
-
Patent Title: Injection syringe Nov. 27, 2012
-
Patent Title: Dose setting limiter Nov. 23, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded to NVO from public contracts
Recent insights relating to NVO
Recent picks made for NVO stock on CNBC
ETFs with the largest estimated holdings in NVO
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $NVO stock a Buy, Sell, or Hold?
- What is the price target for $NVO stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $NVO stock?
- Who owns the most shares of $NVO stock?
- What funds own $NVO stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view NVO Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.